Prevalence of osteoporosis in men in a VA Rehabilitation Center

American Journal of Managed Care

Volumn 16, Issue 6, 2010, Pages 427-433

  Swislocki, Arthur ^a,b   Green, Jon A ^a,b   Heinrich, Gerhard ^a,b   Barnett, Charles A ^a   Meadows, Ivan D ^a   Harmon, Ernest B ^a   Rank, Mary F ^a   Noth, Robert H ^a,b  

^a VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; BODY MASS; BODY WEIGHT; BONE DENSITY; BONE METABOLISM; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR NECK; FUNCTIONAL STATUS; HIP; HOME CARE; HOSPITAL ADMISSION; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; METABOLISM; NURSING HOME; OSTEOPOROSIS; PREVALENCE; PRIORITY JOURNAL; REHABILITATION CENTER; AGE DISTRIBUTION; CASE CONTROL STUDY; DAILY LIFE ACTIVITY; MASS SCREENING; MULTIVARIATE ANALYSIS; NUTRITIONAL STATUS; ORGANIZATION AND MANAGEMENT; PHOTON ABSORPTIOMETRY; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; UNITED STATES; VETERAN;

ABSORPTIOMETRY, PHOTON; ACTIVITIES OF DAILY LIVING; AGE DISTRIBUTION; BODY MASS INDEX; CALIFORNIA; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; HUMANS; LINEAR MODELS; MALE; MASS SCREENING; MULTIVARIATE ANALYSIS; NUTRITIONAL STATUS; OSTEOPOROSIS; PATIENT ADMISSION; PREVALENCE; REHABILITATION CENTERS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; VETERANS;

EID: 77954133350     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Ray NF, Chan JK, Thamer M, Melton LJ 3rd. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997;12(1):24-35.
2. Reginster JY, Deroisy R, Pirenne H, et al. High prevalence of low femoral bone mineral density in elderly women living in nursing homes or community-dwelling: a plausible role of increased parathyroid hormone secretion. Osteoporosis Int. 1999;9(2):121-128. (Pubitemid 29219072)
3. Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med. 1997;103(2A):12S-17S.
4. Kannus P, Parkkari J, Sievänen H, Heinonen A, Vuori I, Järvinen M. Epidemiology of hip fractures. Bone. 1996;18(1 suppl 1):57S-63S.
5. Ebeling PR. Osteoporosis in men. New insights into aetiology, pathogenesis, prevention, and management. Drugs Aging. 1998;13(6):421-434. (Pubitemid 29002720)
6. Ross PD. Osteoporosis. Frequency, consequences, and risk factors. Arch Intern Med. 1996;156(13):1399-1411.
7. Kurland ES, Rosen CJ, Cosman F, et al. Insulin-like growth factor-I in men with idiopathic osteoporosis. J Clin Endocrinol Metab. 1997;82(9):2799-2805. (Pubitemid 27385627)
8. Lips P. Epidemiology and predictors of fractures associated with osteoporosis. Am J Med. 1997;103(2A):3S-8S.
9. Nguyen TV, Eisman JA, Kelly PJ, Sambrook PN. Risk factors for osteoporotic fractures in elderly men. Am J Epidemiol. 1996;144(3):255-263.
10. Gloth FM 3rd, Simonson W. Osteoporosis is underdiagnosed in skilled nursing facilities: a large-scale heel BMD screening study. J Am Med Dir Assoc. 2008;9(3):190-193.
11. Paniagua MA, Malphurs JE, Samos LF. BMI and low bone mass in an elderly male nursing home population. Clin Interv Aging. 2006;1(3):283-287.
12. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest. 1998;102(8):1627-1633. (Pubitemid 28492231)
13. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med. 1997;337(6):382-387.
14. Picado C, Luengo M. Corticosteroid-induced bone loss. Prevention and management. Drug Saf. 1996;15(5):347-359. (Pubitemid 26388658)
15. Gallego-Rojo FJ, Gonzalez-Calvin JL, Muñoz-Torres M, Mundi JL, Fernandez-Perez R, Rodrigo-Moreno D. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology. 1998;28(3):695-699. (Pubitemid 28405418)
16. Khosla S, Hassoun AA, Baker BK, et al. Insulin-like growth factor system abnormalities in hepatitis C-associated osteosclerosis. Potential insights into increasing bone mass in adults. J Clin Invest. 1998;101(10):2165-2173.
17. Tsuneoka K, Tameda Y, Takase K, Nakano T. Osteodystrophy in patients with chronic hepatitis and liver cirrhosis. J Gastroenterol. 1996;31(5):669-678. (Pubitemid 26345533)
18. Chen CC, Wang SS, Jeng FS, Lee SD. Metabolic bone disease of liver cirrhosis: is it parallel to the clinical severity of cirrhosis? J Gastroenterol Hepatol. 1996;11(5):417-421. (Pubitemid 126426135)
19. Runge M, Schacht R. Proximal femoral fractures in the elderly: pathogenesis, sequelae, interventions [in German]. Rehabilitation. 1999;38(3):160-169.
20. Zimmerman SI, Girman CJ, Buie VC, et al. The prevalence of osteoporosis in nursing home residents. Osteoporosis Int. 1999;9(2):151-157. (Pubitemid 29219077)
21. Evans WJ. Exercise training guidelines for the elderly. Med Sci Sports Exer. 1999;31(1):12-17.
22. Slemenda C. Prevention of hip fractures: risk factor modification. Am J Med. 1997;103(2A):65S-71S.
23. The WHO Study Group. Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis. Geneva: World Health Organization; 1994.
24. Lufkin EG, Wanner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 1992;117(1):1-9.
25. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclic etidronate treatment of postmenopausal osteoporosis. N Engl J Med. 1990;323(2):73-79.
26. Ohlsson C, Bengtsson BA, Isaksson OG, Slootweg MC. Growth hormone and bone. Endocr Rev. 1998;19(1):55-79.
27. Eastell R, Boyle IT, Compston J, et al. Management of male osteoporosis: report of the UK Consensus Group. QJM. 1998;91(2):71-92. (Pubitemid 28102662)
28. Hannon R, Blumsohn A Naylor K, Eastell R. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res. 1998;13(7):1124-1133. (Pubitemid 28311780)
29. Crosbie OM, Freaney R, McKenna MJ, Hegarty JE. Bone density, vitamin D status, and disordered bone remodeling in end-stage chronic liver disease. Calcif Tissue Int. 1999;64(4):295-300. (Pubitemid 29165354)
30. Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res. 1998;13(9):1431-1438. (Pubitemid 28418909)
31. Murphy MG, Bach MA, Plotkin D, et al. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group. J Bone Miner Res. 1999;14(7):1182-1188. (Pubitemid 29314062)
32. Bauer DC, Sklarin PM, Stone KL, et al. Biochemical markers of bone turnover and prediction of hip bone loss in older women: the study of osteoporotic fractures. J Bone Miner Res. 1999;14(8):1404-1410.
33. Gamero P, Somay-Rendu E, Duboeuf F, Delmas PD. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY Study. J Bone Miner Res. 1999;14(9):1614-1621. (Pubitemid 29416689)
34. Watts NB. Clinical utility of biochemical markers of bone remodeling. Clin Chem. 1999;45(8, pt 2):1359-1368. (Pubitemid 29422076)
35. Braga de Castro Machado A, Hannon R, Eastell R. Monitoring alendronate therapy for osteoporosis. J Bone Miner Res. 1999;14(4):602-608.
36. Yilmaz N, Bayram M, Erbåǧci AB, Kilinçer MS. Diagnostic value of biochemical markers of bone turnover and postmenopausal osteoporosis. Clin Chem Lab Med. 1999;37(2):137-143. (Pubitemid 29139781)
37. Gamero R Delmas PD. Biochemical markers of bone turnover. Applications for osteoporosis. Endocr Metab Clin North Am. 1998;27(2):303-323.
38. de Vernejoul MC. Markers of bone remodelling in metabolic bone disease. Drugs Aging. 1998;12(suppl 1):9-14. (Pubitemid 28260649)
39. Bikle DD. Biochemical markers in the assessment of bone disease. Am J Med. 1997;103(5):427-436. (Pubitemid 27506250)
40. Swislocki A, Barnett CA, Darnell P, Noth RH. Hyperthyroidism: an underappreciated cause of diffuse bone disease. Clin Nucl Med. 1998;23(4):241-243. (Pubitemid 28158115)
41. Centers for Medicare & Medicaid Services. MDS 2.0 public quality indicator and resident reports. Overview. http://www.cms.gov/MDSPubQIandResRep/. Accessed April 23, 2010.
42. Hodgson SF, Watts NB, Bilezikian JR et al; AACE Osteoporosis Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003 [published correction appears in Endocr Pract. multiple author names added. Endocr Pract. 2004;10(1):90]. Endocr Pract. 2003;9(6):544-564.
43. Dawson-Saunders B, Trapp RG. Basic and Clinical Biostatistics. Norwalk, CT: Appleton and Lange; 1990.
44. Aspray TJ, Stevenson P, Abdy SE, et al. Low bone mineral density measurements in care home residents - a treatable cause of fractures. Age Ageing. 2006;35(1):37-41. (Pubitemid 43124919)
45. Becker C, Crow S, Toman J, et al. Characteristics of elderly patients admitted to an urban tertiary care hospital with osteoporotic fractures: correlations with risk factors, fracture type, gender and ethnicity. Osteoporos Int. 2006;17(3):410-416.
46. Tucci JR. Importance of early diagnosis and treatment of osteoporosis to prevent fractures. Am J Manag Care. 2006;12(7 suppl):S181-S190. (Pubitemid 43764988)
47. Amin S. Male osteoporosis: epidemiology and pathophysiology. Curr Osteoporos Rep. 2003;1(2):71-77.
48. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes [published corrections appear in J Clin Nutr. 2006;84(5):1253. Dosage error in published abstract; MEDLINE/PubMed abstract corrected. Am J Clin Nutr. 2007;86(3):809. Dosage error in published abstract; MEDLINE/PubMed abstract corrected]. Am J Clin Nutr. 2006;84:18-28.
49. Heaney RP. Barriers to optimizing vitamin D3 intake for the elderly. J Nutr. 2006;136(4):1123-1125.
50. Dawson-Hughes B. Racial/ethnic considerations in making recommendations for vitamin D for adult and elderly men and women. Am J Clin Nutr. 2004;80(6 suppl):1763S-1766S.
51. Feldstein AC, Nichols G, Orwoll E, et al. The near absence of osteoporosis treatment in older men with fractures. Osteoporos Int. 2005;16(8):953-962. (Pubitemid 41127105)
52. Dukas L, Staehelin HB, Schacht E, Bischoff HA. Better functional mobility in community-dwelling elderly is related to D-hormone serum levels and to daily calcium intake. J Nutr Health Aging. 2005;9(5):347-351. (Pubitemid 41499864)
53. Davis JW, Ross PD, Preston SD, Nevitt MC, Wasnich RD. Strength, physical activity, and body mass index: relationship to performance-based measures and activities of daily living among older Japanese women in Hawaii. J Am Geriatr Soc. 1998;46(3):274-279.
54. Oka H, Yoshimura N, Kinoshita H, et al. Decreased activities of daily living and associations with bone loss among aged residents in a rural Japanese community: the Miyama Study. J Bone Miner Metab. 2006;24(4):307-313. (Pubitemid 43992674)
55. Nakai Y, Noth R, Wexler J, Volpp B, Tsodikov A, Swislocki A. Computer-based screening of chest x-rays for vertebral compression fractures as an osteoporosis index in men. Bone. 2008;42(6):1214-1218.
56. Rojas-Femandez CH, Lapane KL, MacKnight C, Howard KA. Undertreatment of osteoporosis in residents of nursing homes: population-based study with use of the Systematic Assessment of Geriatric drug use via Epidemiology (SAGE) database. Endocr Pract. 2002;8(5):335-342.
57. Sharma S, Fraser M, Lovell F, Reece A, McLellan AR. Characteristics of males over 50 years who present with a fracture: epidemiology and underlying risk factors. J Bone Joint Surg Br. 2008;90(1):72-77. (Pubitemid 351184795)
58. Melhus H, Risérus U, Warensjö E, et al. A high activity index of stearoyl-CoA desaturase is associated with increased risk of fracture in men. Osteoporos Int. 2008;19(7):929-934.
59. Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ 3rd, Khaltaev N. A reference standard for the description of osteoporosis. Bone. 2008;42(3):467.